271 related articles for article (PubMed ID: 21372036)
1. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.
Cramer DW; Bast RC; Berg CD; Diamandis EP; Godwin AK; Hartge P; Lokshin AE; Lu KH; McIntosh MW; Mor G; Patriotis C; Pinsky PF; Thornquist MD; Scholler N; Skates SJ; Sluss PM; Srivastava S; Ward DC; Zhang Z; Zhu CS; Urban N
Cancer Prev Res (Phila); 2011 Mar; 4(3):365-74. PubMed ID: 21372036
[TBL] [Abstract][Full Text] [Related]
2. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.
Zhu CS; Pinsky PF; Cramer DW; Ransohoff DF; Hartge P; Pfeiffer RM; Urban N; Mor G; Bast RC; Moore LE; Lokshin AE; McIntosh MW; Skates SJ; Vitonis A; Zhang Z; Ward DC; Symanowski JT; Lomakin A; Fung ET; Sluss PM; Scholler N; Lu KH; Marrangoni AM; Patriotis C; Srivastava S; Buys SS; Berg CD;
Cancer Prev Res (Phila); 2011 Mar; 4(3):375-83. PubMed ID: 21372037
[TBL] [Abstract][Full Text] [Related]
3. A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort.
Terry KL; Schock H; Fortner RT; Hüsing A; Fichorova RN; Yamamoto HS; Vitonis AF; Johnson T; Overvad K; Tjønneland A; Boutron-Ruault MC; Mesrine S; Severi G; Dossus L; Rinaldi S; Boeing H; Benetou V; Lagiou P; Trichopoulou A; Krogh V; Kuhn E; Panico S; Bueno-de-Mesquita HB; Onland-Moret NC; Peeters PH; Gram IT; Weiderpass E; Duell EJ; Sanchez MJ; Ardanaz E; Etxezarreta N; Navarro C; Idahl A; Lundin E; Jirström K; Manjer J; Wareham NJ; Khaw KT; Byrne KS; Travis RC; Gunter MJ; Merritt MA; Riboli E; Cramer DW; Kaaks R
Clin Cancer Res; 2016 Sep; 22(18):4664-75. PubMed ID: 27060155
[TBL] [Abstract][Full Text] [Related]
4. The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource.
Zhu CS; Huang WY; Pinsky PF; Berg CD; Sherman M; Yu KJ; Carrick DM; Black A; Hoover R; Lenz P; Williams C; Hawkins L; Chaloux M; Yurgalevitch S; Mathew S; Miller A; Olivo V; Khan A; Pretzel SM; Multerer D; Beckmann P; Broski KG; Freedman ND
Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1635-1642. PubMed ID: 27635065
[TBL] [Abstract][Full Text] [Related]
5. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
6. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC
Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433
[TBL] [Abstract][Full Text] [Related]
7. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status.
Gohagan JK; Prorok PC; Hayes RB; Kramer BS;
Control Clin Trials; 2000 Dec; 21(6 Suppl):251S-272S. PubMed ID: 11189683
[TBL] [Abstract][Full Text] [Related]
8. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
9. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
Han C; Bellone S; Siegel ER; Altwerger G; Menderes G; Bonazzoli E; Egawa-Takata T; Pettinella F; Bianchi A; Riccio F; Zammataro L; Yadav G; Marto JA; Penet MF; Levine DA; Drapkin R; Patel A; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2018 Jun; 149(3):585-591. PubMed ID: 29572027
[TBL] [Abstract][Full Text] [Related]
10. Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.
Prorok PC; Wright P; Riley TR; Kramer BS; Berg CD; Gohagan JK
Rev Recent Clin Trials; 2018; 13(4):257-273. PubMed ID: 29629665
[TBL] [Abstract][Full Text] [Related]
11. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis.
Li F; Tie R; Chang K; Wang F; Deng S; Lu W; Yu L; Chen M
BMC Cancer; 2012 Jun; 12():258. PubMed ID: 22712526
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
13. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
[TBL] [Abstract][Full Text] [Related]
14. Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.
Blyuss O; Gentry-Maharaj A; Fourkala EO; Ryan A; Zaikin A; Menon U; Jacobs I; Timms JF
Biomed Res Int; 2015; 2015():681416. PubMed ID: 26819954
[TBL] [Abstract][Full Text] [Related]
15. Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.
Xi QP; Pu DH; Lu WN
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4536-4541. PubMed ID: 29131263
[TBL] [Abstract][Full Text] [Related]
16. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
[TBL] [Abstract][Full Text] [Related]
17. Iron homeostasis and distal colorectal adenoma risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Cross AJ; Sinha R; Wood RJ; Xue X; Huang WY; Yeager M; Hayes RB; Gunter MJ
Cancer Prev Res (Phila); 2011 Sep; 4(9):1465-75. PubMed ID: 21685236
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
19. The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis.
Olsen M; Lof P; Stiekema A; van den Broek D; Wilthagen EA; Bossuyt PM; Lok CAR
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1788-1799. PubMed ID: 34212386
[TBL] [Abstract][Full Text] [Related]
20. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
